| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Leslie L Iversen last filed a Form 4 in April 2016, as Director at ACAD. Leslie L Iversen's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 36,127 shares of ACAD. The ACAD filings lean toward selling, a net 63,697 shares.
Leslie L Iversen has 6 Form 4 filings on record from June 2015 to April 2016, all as Director at Acadia Pharmaceuticals (ACAD), 2015–2016.
The 12 reported transactions were 9 option exercises, 2 open-market sales and 1 option or other derivative award.
Counted by filing, the open-market trades come to no purchases and 2 sales worth about $2.2M.
The largest open-market sale was 33,697 shares of ACAD at an average $33.53 on April 18, 2016, about $1.1M.
Shares as reported in the last Form 4 for each company; the most recent is from April 2016. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.